Cetera Advisors LLC reduced its position in Allergan plc (NYSE:AGN) by 1.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 45,723 shares of the company’s stock after selling 674 shares during the quarter. Cetera Advisors LLC’s holdings in Allergan were worth $7,705,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Cacti Asset Management LLC lifted its stake in shares of Allergan by 0.9% in the second quarter. Cacti Asset Management LLC now owns 215,018 shares of the company’s stock worth $35,908,000 after buying an additional 2,009 shares in the last quarter. Boltwood Capital Management lifted its stake in shares of Allergan by 25.9% in the second quarter. Boltwood Capital Management now owns 4,985 shares of the company’s stock worth $835,000 after buying an additional 1,025 shares in the last quarter. Fulton Bank N.A. lifted its stake in shares of Allergan by 19.9% in the second quarter. Fulton Bank N.A. now owns 14,220 shares of the company’s stock worth $2,381,000 after buying an additional 2,360 shares in the last quarter. Woodstock Corp lifted its stake in shares of Allergan by 1.4% in the second quarter. Woodstock Corp now owns 14,532 shares of the company’s stock worth $2,433,000 after buying an additional 200 shares in the last quarter. Finally, Metropolis Capital Ltd lifted its stake in shares of Allergan by 41.5% in the second quarter. Metropolis Capital Ltd now owns 321,088 shares of the company’s stock worth $53,760,000 after buying an additional 94,220 shares in the last quarter. 80.64% of the stock is currently owned by institutional investors.
A number of equities analysts have commented on the stock. Guggenheim downgraded shares of Allergan from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Svb Leerink reaffirmed a “market perform” rating and set a $188.00 target price (down from $217.00) on shares of Allergan in a research note on Thursday, July 18th. ValuEngine downgraded shares of Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, October 30th. Sanford C. Bernstein downgraded shares of Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 target price on the stock. in a research note on Tuesday, July 16th. Finally, Cantor Fitzgerald lifted their target price on shares of Allergan from $125.00 to $165.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the stock. Allergan currently has a consensus rating of “Hold” and an average target price of $175.16.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $4.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $4.25. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. The business had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $3.88 billion. During the same period last year, the business earned $4.25 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. As a group, sell-side analysts expect that Allergan plc will post 16.94 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Wednesday, November 13th will be given a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.63%. The ex-dividend date is Tuesday, November 12th. Allergan’s dividend payout ratio is presently 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: Technical Analysis of Stocks, How Can It Help
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.